Litcius/Paper detail

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Quincy S. Chu, Federica Perrone, Laurent Greillier, Wei Tu, Maria Carmela Piccirillo, Federica Grosso, Giuseppe Lo Russo, Marie Florescu, Manlio Mencoboni, Alessandro Morabito, Fabiana Letizia Cecere, Giovanni Luca Ceresoli, David E. Dawe, Paolo Andrea Zucali, Maria Pagano, John R. Goffin, Myriam Locatelli Sanchez, Cesare Gridelli, Gérard Zalcman, Xavier Quantin, Virginie Westeel, Piera Gargiulo, Sara Delfanti, Dongsheng Tu, Christopher W. Lee, Natasha B. Leighl, Joana Sederias, Pamela Brown-Walker, Yiwen Luo, Sylvie Lantuéjoul, Ming‐Sound Tsao, Arnaud Scherpereel, Penelope A. Bradbury, Scott A. Laurie, Lesley Seymour

2023The Lancet101 citationsDOI

Topics & Concepts

PembrolizumabMedicineChemotherapyOpen labelMesotheliomaInternal medicineOncologyRandomized controlled trialPathologyCancerImmunotherapyOccupational and environmental lung diseasesPleural and Pulmonary DiseasesCancer Immunotherapy and Biomarkers